phase III randomized Intergroup … (2024)

phase III randomized Intergroup … (1) https://doi.org/10.1200/jco.1998.16.4.1310 · phase III randomized Intergroup … (2) Full text

Journal: Journal of Clinical Oncology, 1998, №4, p.1310-1317

Publisher: American Society of Clinical Oncology (ASCO)

Authors:

  1. M Al-Sarraf
  2. M LeBlanc
  3. P G Giri
  4. K K Fu
  5. J Cooper
  6. T Vuong
  7. A A Forastiere
  8. G Adams
  9. W A Sakr
  10. D E Schuller
  11. J F Ensley

Abstract

<jats:sec>PURPOSE The Southwest Oncology Group (SWOG) coordinated an Intergroup study with the participation of Radiation Therapy Oncology Group (RTOG), and Eastern Cooperative Oncology Group (ECOG). This randomized phase III trial compared chemoradiotherapy versus radiotherapy alone in patients with nasopharyngeal cancers. </jats:sec><jats:sec>MATERIALS AND METHODS Radiotherapy was administered in both arms: 1.8- to 2.0-Gy/d fractions Monday to Friday for 35 to 39 fractions for a total dose of 70 Gy. The investigational arm received chemotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43 during radiotherapy; postradiotherapy, chemotherapy with cisplatin 80 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/d on days 1 to 4 was administered every 4 weeks for three courses. Patients were stratified by tumor stage, nodal stage, performance status, and histology. </jats:sec><jats:sec>RESULTS Of 193 patients registered, 147 (69 radiotherapy and 78 chemoradiotherapy) were eligible for primary analysis for survival and toxicity. The median progression-free survival (PFS) time was 15 months for eligible patients on the radiotherapy arm and was not reached for the chemo-radiotherapy group. The 3-year PFS rate was 24% versus 69%, respectively (P &lt; .001). The median survival time was 34 months for the radiotherapy group and not reached for the chemo-radiotherapy group, and the 3-year survival rate was 47% versus 78%, respectively (P = .005). One hundred eighty-five patients were included in a secondary analysis for survival. The 3-year survival rate for patients randomized to radiotherapy was 46%, and for the chemoradiotherapy group was 76% (P &lt; .001). </jats:sec><jats:sec>CONCLUSION We conclude that chemoradiotherapy is superior to radiotherapy alone for patients with advanced nasopharyngeal cancers with respect to PFS and overall survival. </jats:sec>

Publications that cite this publication

Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck

Mohan Suntharalingam, Michael L. Haas, David A. Van Echo, Robert Haddad, Maria C. Jacobs, Sharon Levy, William C. Gray, Robert A. Ord, Barbara A. Conley

phase III randomized Intergroup … (3) https://doi.org/10.1002/1097-0142(20010201)91:3<548::aid-cncr1033>3.0.co;2-a · phase III randomized Intergroup … (4)

2001, Cancer, №3, p.548-554

Scopus

WoS

Crossref citations:31

The role of chemotherapy in the primary management of nasopharyngeal cancer

D.J. Adelstein

phase III randomized Intergroup … (5) https://doi.org/10.1046/j.1365-2273.2000.00329-7.x

2000, Clinical Otolaryngology, №1, p.77-78

Scopus

Crossref citations:0

Nasopharyngeal carcinoma in children under 15 years of age: A retrospective review of 65 patients

S. Sahraoui, A. Acharki, A. Benider, N. Bouras, A. Kahlain

phase III randomized Intergroup … (6) https://doi.org/10.1023/a:1008325925164 · phase III randomized Intergroup … (7) Full text

1999, Annals of Oncology, №12, p.1499-1502

Scopus

WoS

Crossref citations:31

Plasma Epstein-Barr Virus MicroRNA BART8-3p as a Diagnostic and Prognostic Biomarker in Nasopharyngeal Carcinoma

Cheng Lin, Keyu Lin, Bin Zhang, Ying Su, Qiaojuan Guo, Tianzhu Lu, Yuanji Xu, Shaojun Lin, Jingfeng Zong, Jianji Pan

phase III randomized Intergroup … (8) https://doi.org/10.1093/oncolo/oyac024 · phase III randomized Intergroup … (9)

2022, The Oncologist, №4, p.e340-e349

Scopus

WoS

Crossref citations:8

Determination of tumor kinetics: strategies for the delivery of radiotherapy and chemotherapy

Mark A. Ritter

phase III randomized Intergroup … (10) https://doi.org/10.1097/00001622-199905000-00007

1999, Current Opinion in Oncology, №3, p.177

Scopus

WoS

Crossref citations:7

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer

Richard H. Wheeler, Sharon Spencer, Donald Buchsbaum, Francisco Robert

phase III randomized Intergroup … (11) https://doi.org/10.1097/00001622-199905000-00009

1999, Current Opinion in Oncology, №3, p.187

Scopus

WoS

Crossref citations:14

Surgical options for continuing treatment of recurrent nasopharyngeal carcinoma

William Ignace Wei, Anthony Po Wing Yuen, Wai Kuen Ho

phase III randomized Intergroup … (12) https://doi.org/10.1097/00020840-200004000-00009

2000, Current Opinion in Otolaryngology &amp; Head and Neck Surgery, №2, p.117-121

Scopus

WoS

Crossref citations:3

Hyperfractionated Radiotherapy Followed by Adjuvant Chemotherapy for Nasopharyngeal Cancer: Report of Seven Cases

T. Toita, K. Ogawa, M. Kamata, S. Kojya, T. Itokazu, Y. Kakinohana, S. Iraha, M. Yoshinaga, Y. Zukeran, S. Sawada

phase III randomized Intergroup … (13) https://doi.org/10.1093/jjco/29.3.160 · phase III randomized Intergroup … (14) Full text

1999, Japanese Journal of Clinical Oncology, №3, p.160-163

Scopus

WoS

Crossref citations:1

Long-Term Follow-up on an Intensified Treatment Regimen for Advanced Resectable Head and Neck Squamous Cell Carcinomas

John C. Grecula, David E. Schuller, Roy Smith, Chris A. Rhoades, Subir Nag, Constance J. Bauer, Amit Agrawal, Jessie L.-S. Au, Donn Young, Reinhard A. Gahbauer

phase III randomized Intergroup … (15) https://doi.org/10.1081/cnv-100000147 · phase III randomized Intergroup … (16)

2001, Cancer Investigation, №2, p.127-136

Scopus

WoS

Crossref citations:3

A New Intensified Therapeutic Regimen for Advanced Head and Neck Squamous Cell Carcinomas: Where Does It Fit Among Available Treatment Options?

David G. Pfister, Eric J. Sherman, Suzanne L. Wolden

phase III randomized Intergroup … (17) https://doi.org/10.1081/cnv-100000157 · phase III randomized Intergroup … (18)

2001, Cancer Investigation, №2, p.217-218

Scopus

WoS

Crossref citations:0

Find all citations of the publication

phase III randomized Intergroup … (2024)
Top Articles
Latest Posts
Recommended Articles
Article information

Author: Moshe Kshlerin

Last Updated:

Views: 5379

Rating: 4.7 / 5 (77 voted)

Reviews: 92% of readers found this page helpful

Author information

Name: Moshe Kshlerin

Birthday: 1994-01-25

Address: Suite 609 315 Lupita Unions, Ronnieburgh, MI 62697

Phone: +2424755286529

Job: District Education Designer

Hobby: Yoga, Gunsmithing, Singing, 3D printing, Nordic skating, Soapmaking, Juggling

Introduction: My name is Moshe Kshlerin, I am a gleaming, attractive, outstanding, pleasant, delightful, outstanding, famous person who loves writing and wants to share my knowledge and understanding with you.